Literature DB >> 24331186

Radiosensitizers in pancreatic cancer--preclinical and clinical exploits with molecularly targeted agents.

Amanda J Walker, Sara R Alcorn, Amol K Narang, Katriana M Nugent, Aaron T Wild, Joseph M Herman, Phuoc T Tran.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24331186      PMCID： PMC3868005          DOI： 10.1016/j.currproblcancer.2013.10.008

Source DB:  PubMed          Journal:  Curr Probl Cancer        ISSN： 0147-0272            Impact factor:   3.187


× No keyword cloud information.
  106 in total

1.  Functional proteomics of transforming growth factor-beta1-stimulated Mv1Lu epithelial cells: Rad51 as a target of TGFbeta1-dependent regulation of DNA repair.

Authors:  Takashi Kanamoto; Ulf Hellman; Carl-Henrik Heldin; Serhiy Souchelnytskyi
Journal:  EMBO J       Date:  2002-03-01       Impact factor: 11.598

2.  One thousand consecutive pancreaticoduodenectomies.

Authors:  John L Cameron; Taylor S Riall; JoAnn Coleman; Kenneth A Belcher
Journal:  Ann Surg       Date:  2006-07       Impact factor: 12.969

Review 3.  Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology.

Authors:  Søren M Bentzen
Journal:  Nat Rev Cancer       Date:  2006-09       Impact factor: 60.716

4.  A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response.

Authors:  Zhao Chen; Katherine Cheng; Zandra Walton; Yuchuan Wang; Hiromichi Ebi; Takeshi Shimamura; Yan Liu; Tanya Tupper; Jing Ouyang; Jie Li; Peng Gao; Michele S Woo; Chunxiao Xu; Masahiko Yanagita; Abigail Altabef; Shumei Wang; Charles Lee; Yuji Nakada; Christopher G Peña; Yanping Sun; Yoko Franchetti; Catherine Yao; Amy Saur; Michael D Cameron; Mizuki Nishino; D Neil Hayes; Matthew D Wilkerson; Patrick J Roberts; Carrie B Lee; Nabeel Bardeesy; Mohit Butaney; Lucian R Chirieac; Daniel B Costa; David Jackman; Norman E Sharpless; Diego H Castrillon; George D Demetri; Pasi A Jänne; Pier Paolo Pandolfi; Lewis C Cantley; Andrew L Kung; Jeffrey A Engelman; Kwok-Kin Wong
Journal:  Nature       Date:  2012-03-18       Impact factor: 49.962

5.  Phase-II study on stereotactic radiotherapy of locally advanced pancreatic carcinoma.

Authors:  Morten Hoyer; Henrik Roed; Lisa Sengelov; Anders Traberg; Lars Ohlhuis; Jorgen Pedersen; Hanne Nellemann; Anne Kiil Berthelsen; Frey Eberholst; Svend Aage Engelholm; Hans von der Maase
Journal:  Radiother Oncol       Date:  2005-07       Impact factor: 6.280

6.  Epidermal growth factor receptor blockade with C225 modulates proliferation, apoptosis, and radiosensitivity in squamous cell carcinomas of the head and neck.

Authors:  S M Huang; J M Bock; P M Harari
Journal:  Cancer Res       Date:  1999-04-15       Impact factor: 12.701

7.  Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva).

Authors:  Prakash Chinnaiyan; Shyhmin Huang; Geetha Vallabhaneni; Eric Armstrong; Sooryanarayana Varambally; Scott A Tomlins; Arul M Chinnaiyan; Paul M Harari
Journal:  Cancer Res       Date:  2005-04-15       Impact factor: 12.701

8.  A phase I study of erlotinib in combination with gemcitabine and radiation in locally advanced, non-operable pancreatic adenocarcinoma.

Authors:  A Duffy; J Kortmansky; G K Schwartz; M Capanu; S Puleio; B Minsky; L Saltz; D P Kelsen; E M O'Reilly
Journal:  Ann Oncol       Date:  2007-09-17       Impact factor: 32.976

9.  Identification and biological evaluation of a novel and potent small molecule radiation sensitizer via an unbiased screen of a chemical library.

Authors:  Brian E Lally; Geoffrey A Geiger; Steven Kridel; Alice E Arcury-Quandt; Michael E Robbins; Nancy D Kock; Kenneth Wheeler; Prakash Peddi; Alexandros Georgakilas; Gary D Kao; Constantinos Koumenis
Journal:  Cancer Res       Date:  2007-09-15       Impact factor: 12.701

10.  Non-oncogene addiction and the stress phenotype of cancer cells.

Authors:  Nicole L Solimini; Ji Luo; Stephen J Elledge
Journal:  Cell       Date:  2007-09-21       Impact factor: 41.582
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.